Clinical Trial Update: Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, pharmacokinetics, and impact on inflammation of oral BI 1026706 in patients with chronic obstructive pulmonary di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BI 1026706 (BI 1026706)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED | Results posted: 2019-08-05